Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma.
about
Loss of a 20S proteasome activator in Saccharomyces cerevisiae downregulates genes important for genomic integrity, increases DNA damage, and selectively sensitizes cells to agents with diverse mechanisms of actionRole of proteasomes in disease.Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myelomaCirculating proteasome activity following mild head injury in childrenProteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.The treatment of traumatic brain injury with velcade.Circulating proteasomes after burn injuryIncreased proteasome activator 28 gamma (PA28γ) levels are unspecific but correlate with disease activity in rheumatoid arthritis.Circulating 20S proteasome is independently associated with abdominal muscle mass in hemodialysis patients.Particulate cytoplasmic structures with high concentration of ubiquitin-proteasome accumulate in myeloid neoplasms.Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis.Targeting tumor proteasome with traditional Chinese medicine.Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome.FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsClinical development of novel proteasome inhibitors for cancer treatment.Neural cells secrete a unique repertoire of proteinsMyeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis.The 26 S proteasome: from basic mechanisms to drug targeting.Carfilzomib boosted combination therapy for relapsed multiple myelomaImplications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part II: targeting cell cycle events, caspases, NF-κB and the proteasome.The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma.SPR imaging biosensor for the 20S proteasome: sensor development and application to measurement of proteasomes in human blood plasma.Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells.A preliminary study of the effect of curcumin on the expression of p53 protein in a human multiple myeloma cell line.Plasma proteasomal chymotrypsin-like activity correlates with prostate cancer progression.Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance.T lymphocytes export proteasomes by way of microparticles: a possible mechanism for generation of extracellular proteasomes.The case for therapeutic proteostasis modulatorsAlveolar extracellular 20S proteasome in patients with acute respiratory distress syndrome.Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.Proteomic analysis of affinity-purified extracellular proteasomes reveals exclusively 20S complexes.Proteasome and C-reactive protein inflammatory response in children undergoing shorter and longer lasting laparoscopic cholecystectomy.Immunoproteasome in the blood plasma of children with acute appendicitis, and its correlation with proteasome and UCHL1 measured by SPR imaging biosensors.Circulating extracellular proteasome in the cerebrospinal fluid: a study on concentration and proteolytic activity.Concentration of Proteasome in the Blood Plasma of Children with Acute Appendicitis, Before and After Surgery, and Its Correlation with CRP.Circulating proteasomes: circling myeloma with a new potential biomarker.Bladder cancer detection using a peptide substrate of the 20S proteasome.
P2860
Q27930325-8C10A5E4-9E9C-4B50-A853-AAED33D7CE28Q33307877-C7BA868C-2A83-48E6-A901-2AA95946FAABQ33677445-95822AD3-D091-44E4-9BE7-D2475F21B1AAQ33810650-EF30931E-B553-4126-9DB1-DA56111F85ACQ33880813-92228A90-7AE8-4947-9F75-14B0D597B5F3Q34254813-CEBDD1B3-3F69-4F96-8058-50D0DD01B271Q34665247-011CE699-69A6-4142-BD78-7A075481EFB0Q34967751-5DAC60DF-7AEA-4610-887D-DF16DAC7C555Q35214455-266AA8BC-7AC4-41D9-90B8-8327DF6302EEQ35759402-90B7D3C2-C09F-48D8-BDC9-B4D13008369CQ35835132-CCC54363-8C84-4AA6-9116-8DF3F54B1150Q35835298-00A5B119-7410-496D-8965-C816FD8FE5AFQ36125132-55261D40-7250-4A67-A5D6-212CB95AB113Q36293871-B456BA9D-4CB6-4334-BD06-87E0036AEB27Q37017342-18E9BE8E-9DF8-4EB0-9FEA-09E31AC0B713Q37136598-5CA789B6-5B04-488E-B72B-A2F2DB3EC1FBQ37178891-0F1E24B2-2755-4091-9E8F-9E9D4D4C9C8DQ37365560-F6B55543-66AF-4D13-AE90-447659D05339Q37541906-6FF104F4-2778-4FB5-9E1D-E692F4701517Q37610623-57D67D9E-5A3B-4026-A95F-0200F0E96752Q37652953-81CF3E56-74CB-48CC-8DB7-5788E1B888A6Q38088360-753C5530-D431-47FA-B659-1BECF5D5B65EQ38164821-A4EC8733-2EB0-4481-B35B-4E3B21EF2D36Q38559057-E2BED331-CB27-4A1E-80B3-C7239BFD99D4Q38822625-E7FC3B3A-41CD-429B-8BF0-AD2CF6CA42E8Q38897664-DDF21349-F58B-41E7-8E6C-9CB36523AECEQ38921156-B951A28C-3D45-4F90-A761-485737B609C3Q39336938-DDBE830F-3F80-459C-B59D-97C6132718E9Q40521248-FFDEB47F-C0B6-4F66-9179-DD581FAA9487Q41923180-4AD0F9C8-7F49-48B3-AE0B-91E87C52E626Q42245016-4D60E9A0-1AF2-47A3-8642-F4E79DEB2C43Q46088115-75341DA4-D4B9-4D2B-9170-A8B6F4E46D97Q46246952-66C60475-D085-4AB6-A595-35AC9F117D4DQ47280042-0B4BD66B-F67D-4FAB-87C1-9838AA795D2EQ47664209-B34E8E6E-BAB6-4631-8F29-BB6AE7EBAB6AQ47757096-54A7AA85-719C-478D-8D33-6EEA4C63B7A7Q48923815-164808DB-93BC-45A8-BC7D-404830251590Q49630129-EC411EF4-2E1B-4EF9-9EA0-4572D4DE9288Q52751890-48B31706-C037-476B-99F4-E1E759AE342AQ53037193-6B31E35B-B6F7-4557-8BD6-3726CD6041BA
P2860
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Circulating proteasome levels ...... survival in multiple myeloma.
@ast
Circulating proteasome levels ...... survival in multiple myeloma.
@en
Circulating proteasome levels ...... survival in multiple myeloma.
@nl
type
label
Circulating proteasome levels ...... survival in multiple myeloma.
@ast
Circulating proteasome levels ...... survival in multiple myeloma.
@en
Circulating proteasome levels ...... survival in multiple myeloma.
@nl
prefLabel
Circulating proteasome levels ...... survival in multiple myeloma.
@ast
Circulating proteasome levels ...... survival in multiple myeloma.
@en
Circulating proteasome levels ...... survival in multiple myeloma.
@nl
P2093
P50
P1433
P1476
Circulating proteasome levels ...... survival in multiple myeloma.
@en
P2093
Christian Jakob
Claudia Fleissner
Eugen Feist
Ivana Zavrski
Lorenz Kleeberg
Martin Kaiser
Orhan Sezer
Peter Liebisch
Seval Türkmen
P304
P356
10.1182/BLOOD-2006-04-016360
P407
P577
2006-11-09T00:00:00Z